BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
Pre-transplant conditioning will include targeted total marrow irradiation (TMI) at a dose of
6Gy. Graft-versus-host disease prophylaxis will include cyclophosphamide 50 mg/kg on Day +3
and 4 along with tacrolimus and mycophenolate mofetil
Phase:
Phase 2
Details
Lead Sponsor:
University of Illinois at Chicago
Treatments:
Complement Factor H Cyclophosphamide Fludarabine Fludarabine phosphate Tacrolimus